These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26634271)

  • 1. Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
    Garcia JS; Huang M; Medeiros BC; Mitchell BS
    Clin Cancer Res; 2016 Apr; 22(8):1978-88. PubMed ID: 26634271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
    Huang M; Thomas D; Li MX; Feng W; Chan SM; Majeti R; Mitchell BS
    Leukemia; 2013 Oct; 27(10):1970-80. PubMed ID: 23877794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 contributes to treatment failure in acute myeloid leukemia.
    Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
    Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
    Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
    Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
    Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
    Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
    Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish.
    Bolli N; Payne EM; Grabher C; Lee JS; Johnston AB; Falini B; Kanki JP; Look AT
    Blood; 2010 Apr; 115(16):3329-40. PubMed ID: 20197555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nontoxic-dose of deguelin induce NPMc+ AML cell differentiation by selectively targeting Mt NPM1/SIRT1 instead of HDAC1/3.
    Wang YP; Yi S; Wen L; Zhang BP; Zhao Z; Hu JY; Zhao F; He J; Fang J; Zhang C; Cui G; Chen Y
    Curr Cancer Drug Targets; 2014; 14(8):685-99. PubMed ID: 25348016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.
    Zhang W; Zhao C; Zhao J; Zhu Y; Weng X; Chen Q; Sun H; Mi JQ; Li J; Zhu J; Chen Z; Pandolfi PP; Chen S; Yan X; Xu J
    Theranostics; 2018; 8(16):4359-4371. PubMed ID: 30214626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.
    Yi S; Wen L; He J; Wang Y; Zhao F; Zhao J; Zhao Z; Cui G; Chen Y
    Ann Hematol; 2015 Feb; 94(2):201-10. PubMed ID: 25242579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
    Andresen V; Erikstein BS; Mukherjee H; Sulen A; Popa M; Sørnes S; Reikvam H; Chan KP; Hovland R; McCormack E; Bruserud Ø; Myers AG; Gjertsen BT
    Cell Death Dis; 2016 Dec; 7(12):e2497. PubMed ID: 27906185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
    Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
    Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
    Dai Q; Ren Y
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XPO1 is a new target of homoharringtonine (HHT): Making NPMc
    Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
    Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunohistochemical demonstration of mutant nucleophosmin in acute myeloid leukemia: biological and clinical features related to NPMc expression].
    Bedekovics J; Rejto L; Telek B; Udvardy M; Ujfalusi A; Oláh E; Hevessy Z; Kappelmayer J; Kajtár B; Méhes G
    Orv Hetil; 2009 May; 150(22):1031-5. PubMed ID: 19465351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.